Zhernakova, Daria V. http://orcid.org/0000-0001-6531-3890
,
Le, Trang H.
Kurilshikov, Alexander http://orcid.org/0000-0003-2541-5627
Atanasovska, Biljana
Bonder, Marc Jan
Sanna, Serena
Claringbould, Annique
Võsa, Urmo
Deelen, Patrick http://orcid.org/0000-0002-5654-3966
Franke, Lude http://orcid.org/0000-0002-5159-8802
de Boer, Rudolf A. http://orcid.org/0000-0002-4775-9140
Kuipers, Folkert
Netea, Mihai G. http://orcid.org/0000-0003-2421-6052
Hofker, Marten H.
Wijmenga, Cisca http://orcid.org/0000-0002-5635-1614
Zhernakova, Alexandra
Fu, Jingyuan http://orcid.org/0000-0001-5578-1236
,
Article History
Received: 9 November 2017
Accepted: 2 August 2018
First Online: 24 September 2018
Change Date: 19 October 2018
Change Type: Correction
Change Details: In the version of this paper originally published, there was a typographical error. In the Discussion, the sentence “In line with this, Ep-CAM-deficient mice exhibited increased intestinal permeability and decreased ion transport<sup>60</sup>, which may contribute to CVD susceptibility risk<sup>59</sup>” originally read iron instead of ion transport. This error has been corrected in the HTML, PDF and print versions of the article.
Competing interests
: Dr. de Boer has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Roche, Trevena, and ThermoFisher GmbH. Dr. de Boer is a minority shareholder of scPharmaceuticals, Inc. Dr. de Boer received personal fees from MandalMed Inc, Novartis, and Servier. All other authors declare no competing interests.